Not Signed In - Rigel Announces Initiation Of Phase 1 Study Evaluating R763 In Hematological Malignancies
Wed, 14 Feb 2007 08:00 AM EST
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced today that its partner Merck Serono has begun enrolling patients in a Phase 1 study evaluating the safety and tolerability of R763, a highly potent, orally available multi-Aurora kinase inhibitor, for the treatment of patients with hematological malignancies. [click link for full article] ...
Related Topics
- Evaluating Health Information
- AIDS-Related Malignancies
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
- Radiation Studies
- Febrile Seizures
- PET Study
- Caregiving
- Clinical Trials
- Peptic Ulcer
- Chondroitin
- Retinoblastoma
- Cyclosporine Ophthalmic
- Schizophrenia
- Ear Candling
- DHEA
- Syphilis
- Galantamine
- Cardiovascular Health
email this page
print this page
bookmark this page
feedback on this page
